<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838812</url>
  </required_header>
  <id_info>
    <org_study_id>IGF 03-42008</org_study_id>
    <nct_id>NCT00838812</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate</brief_title>
  <official_title>Monocentric Study, Prospective, Open and Non Controlled for to Evaluate the Effectiveness, and Tolerability the Safety of Association of Clindamycin Phosphate 1.2% and Tretinoin 0,025% in the Treatment of Acne Vulgaris Mild to Moderate, When Used Once Daily for 12 Weeks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igefarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igefarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of association between
      tretinoin and clindamycin phosphate on the treatment of acne vulgaris mild and moderate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the efficacy, through number of lesions, and tolerability of the product.</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>clindamicin and tretinoin gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>application of the topic gel</intervention_name>
    <description>Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.</description>
    <arm_group_label>clindamicin and tretinoin gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of both sexes with age greater than or equal to 12 years

          -  Subjects diagnosed with acne vulgaris in the face, except for the nasal area, range
             from mild to moderate, with the following requirements.

               -  Mild acne = presence of fewer than 20 comedones or less than 15 lesions,
                  inflammatory lesions or a total of less than 30 injuries.

               -  Moderate acne = presence of 20 the 100 comedones or of 15 the 50 inflamatory
                  lesions or a total of 30 the 125 lesions, with not more than lesions small nodule
                  until 5,0 mm.

          -  Ensure that the existing injuries were not submitted any treatment for acne, topical
             or systemic, within the last 30 days.

          -  Be able to properly follow the determinations of the Protocol.

          -  Has provided a written voluntary consent to participate in the study, by signing the
             informed consent, before being subjected to any procedure.

          -  Under 18 years old, be accompanied by legal guardian in the process of obtaining the
             informed consent.

          -  Be mentally able to provide consent and be fulfilling all the requirements of the
             study.

        Exclusion Criteria:

          -  Pregnant women or in periods of lactation.

          -  Women of childbearing age and sexual activity with not using safe contraceptive
             method, such as oral contraceptives, implantable, injectable or intra-uterine,
             introduced for at least 120 days.

          -  Women who are using oral contraceptives containing the hormone combination for acetate
             ciprosterone and etinolestradiol, association of drospirenone and ethinyl estradiol,
             or desogestrel.

          -  Clinical evidence or history of immunodeficiency.

          -  Any use of immunosuppressive drug and/or immunomodulating over the past 3 months,
             topical or systemic.

          -  Concurrent use of fotossentetizadores, neuromuscular blockers, medications that
             exacerbate the acne, blockers (filters) with solar alcoholic vehicle, spironolactone,
             flutamide or zinc salts.

          -  Prior use of systemic retinoid.

          -  Presence of acne medication and/or cosmetic.

          -  History of systemic metabolic disorder that can interfere with the integrity of the
             skin.

          -  History of inflammatory disease, intestinal or regional enteritis and/or symptoms
             similar.

          -  History of joy to any of the components of the formula (active principle or carrier).

          -  History of abuse of alcohol and/or illegal drugs.

          -  History of non-adherence to medical treatment earlier.

          -  Any clinical observation made by the investigator that prohibits participation in the
             study of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lal Clinica</name>
      <address>
        <city>Valinhos</city>
        <state>SÃ£o Paulo</state>
        <zip>13276-245</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dra. Rosa Maria Scavarelli</name_title>
    <organization>I</organization>
  </responsible_party>
  <keyword>clindamycin</keyword>
  <keyword>tretinoin</keyword>
  <keyword>acne vulgaris</keyword>
  <keyword>Acne vulgaris mild to moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

